Industry News | Animal Health
Knockout of Caveolin-1 and HDAC6 Lifts Foot-and-Mouth Disease Virus Titers in BHK-21 Cells
Published:

A study published in the Journal of Virology on November 16, 2026 reports that deleting two host restriction factors from BHK-21 cells, the line conventionally used to grow foot-and-mouth disease virus for inactivated vaccines, raised virus titers 10- to 20-fold. The authors are based at ICAR's National Centre for Veterinary Type Cultures in Hisar, with collaborators at Biovet Pvt Ltd and the ICMR-National Institute of Virology in Pune.
The team first screened small molecules: baicalein, a caveolin-1 inhibitor, and tubacin, an HDAC6 inhibitor, both increased viral replication. Follow-up experiments assigned the two proteins to different steps. Caveolin-1 restricted viral entry, and its inhibition pushed cells toward p53-dependent apoptosis that promoted cytolytic spread; HDAC6 acted after entry, and inhibiting it increased alpha-tubulin acetylation together with viral RNA and protein expression. Genome editing was then used to remove both genes.
The resulting double-knockout cells produced 10- to 20-fold higher titers in adherent and suspension culture, tested against a field isolate of serotype O and vaccine strains of serotypes O, A and Asia 1. Reintroducing either factor restored the restriction, supporting the interpretation that both genes act as genuine host barriers.
Why yield per cell limits foot-and-mouth vaccine supply
Foot-and-mouth disease control rests largely on repeated herd vaccination with inactivated virus, at a high antigen dose per animal. Output depends on how much virus a culture yields, so gains at the cell level translate into capacity that manufacturers otherwise have to find through more bioreactor volume. The improvement here sits in the substrate rather than in the vaccine strain: the virus is unchanged.
Two barriers at separate points in the replication cycle also matter for how the result generalizes. Removing an entry block and a post-entry block each raised output, and combining them raised it further. For process developers, the transferable logic is that host factors constraining a target virus are candidate engineering targets, and they can be triaged with inhibitors before any permanent edit is made.
The limits of the evidence are as important as the result. Titers are cell-culture measurements; the paper does not report antigen yield after inactivation and formulation, potency in cattle, or protection. Stability of the edited line over many passages, performance in serum-free suspension processes, and acceptance of an engineered substrate all sit between this finding and a licensed vaccine.
What an engineered producer line must still prove
An engineered cell substrate is judged on documentation as much as on output. Practical requirements include clonal identity, confirmed biallelic knockout at both loci, absence of unintended edits, a stable karyotype with consistent growth, and a clean record on adventitious agents. Sequencing at the edited loci, off-target analysis and expression testing form the routine evidence base for those claims.
Manufacturing and biosafety review then asks whether the line behaves predictably at scale, whether the change affects inactivation kinetics, and whether higher infectious titers require adjusted containment. These questions do not weaken the finding; they define the work that converts a titer gain into a validated production change.
Related BioVenic Research Support
BioVenic provides custom animal knockout cell line development based on programmable genome editing, covering guide RNA design and editing-vector construction, cell transfection, selection and clonal isolation by limiting dilution, and sequencing-based confirmation of biallelic knockout together with expression and off-target verification.
